In a randomized clinical trial, tesamorelin reduced visceral adipose tissue and liver fat in HIV-infected patients (Stanley et al., JAMA, 2014), and its Phase 3 program (Falutz et al.) established the visceral-fat effect that underpins its FDA approval
Cell Metabolism, 34(9), 1234-1247.e9
Both require dose escalation to manage GI side effects
What are the licensed alternatives to retatrutide and tesamorelin for weight management in the UK
It means the legal standard for proving manufacturer liability is higher for these specific conditions at this stage
Considering Life Extension promotes its consistent, high-quality testing, we were surprised by these results